Transcription elongation factors represent in vivo cancer dependencies in glioblastoma

Tyler E. Miller, Brian B. Liau, Lisa C. Wallace, Andrew R. Morton, Qi Xie, Deobrat Dixit, Daniel C. Factor, Leo J. Y. Kim, James J. Morrow, Qiulian Wu, Stephen C. Mack, Christopher G. Hubert, Shawn M. Gillespie, William A. Flavahan, Thomas Hoffmann, Rohit Thummalapalli, Michael T. Hemann, Patrick J. Paddison, Craig M. Horbinski, Johannes Zuber, Peter C. Scacheri, Bradley E. Bernstein, Paul J. Tesar () and Jeremy N. Rich ()
Additional contact information
Tyler E. Miller: Lerner Research Institute, Cleveland Clinic
Brian B. Liau: Harvard Medical School
Lisa C. Wallace: Lerner Research Institute, Cleveland Clinic
Andrew R. Morton: Lerner Research Institute, Cleveland Clinic
Qi Xie: Lerner Research Institute, Cleveland Clinic
Deobrat Dixit: Lerner Research Institute, Cleveland Clinic
Daniel C. Factor: Case Western Reserve University School of Medicine
Leo J. Y. Kim: Lerner Research Institute, Cleveland Clinic
James J. Morrow: Case Western Reserve University School of Medicine
Qiulian Wu: Lerner Research Institute, Cleveland Clinic
Stephen C. Mack: Lerner Research Institute, Cleveland Clinic
Christopher G. Hubert: Lerner Research Institute, Cleveland Clinic
Shawn M. Gillespie: Harvard Medical School
William A. Flavahan: Lerner Research Institute, Cleveland Clinic
Thomas Hoffmann: Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC)
Rohit Thummalapalli: Harvard Medical School
Michael T. Hemann: The Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology
Patrick J. Paddison: Fred Hutchinson Cancer Research Center
Craig M. Horbinski: Feinberg School of Medicine, Northwestern University
Johannes Zuber: Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC)
Peter C. Scacheri: Case Western Reserve University School of Medicine
Bradley E. Bernstein: Harvard Medical School
Paul J. Tesar: Case Western Reserve University School of Medicine
Jeremy N. Rich: Lerner Research Institute, Cleveland Clinic

Nature, 2017, vol. 547, issue 7663, 355-359

Abstract: An in vivo RNA interference screening strategy in glioblastoma enabled the identification of a host of epigenetic targets required for glioblastoma cell survival that were not identified by parallel standard screening in cell culture, including the transcription pause–release factor JMJD6, and could be a powerful tool to uncover new therapeutic targets in cancer.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature23000 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:547:y:2017:i:7663:d:10.1038_nature23000

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature23000

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().